At the World Health Organization (WHO) in Geneva, Switzerland, Hospira, Inc. said that it is essential for biosimilar drugs to be given the same nonproprietary names as original biologics. Hospira, the world’s leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, said that biosimilars should …